Pharmabiz

DFE Pharma launches continuous manufacturing platform to accelerate and enable formulation development

DFE Pharma launches continuous manufacturing platform to accelerate and enable formulation development: Goch, Germany Wednesday, February 18, 2026, 12:00 Hrs [IST] DFE Pharma, a g ...

Halozyme Delivers Record FY2025 As 2026 Sets Up A Major Profitability Surge

Halozyme Therapeutics is entering a powerful earnings inflection. FY25 revenue grew 38% to $1.397 billion. Check out why I am bullish on HALO stock.
CURE

FDA OKs Breakthrough Status to Rybrevant Faspro in Head and Neck Cancer

FDA grants breakthrough status to Rybrevant Faspro for recurrent or metastatic HPV-negative head and neck cancer after prior therapy.

TN warns public against purchase of unapproved oral nicotine pouches; notices issued to Amazon, dealers

Tamil Nadu warns against unapproved oral nicotine pouches; advises public to avoid their purchase and use due to health risks.
The Malaysian Reserve

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer

New designation is based on data showing rapid and durable responses in a heavily pretreated patient population and expands the promise of RYBREVANT ...

TN Drug Control Directorte alerts public against purchasing, consumption of Oral Nicotine pouches

The Tamil Nadu Directorate of Drugs Control on Wednesday issued a public <br />notice warning the people against the purchase, sale, and consumption of Oral Nicotine Pouches <br />as they are not ...

Johnson & Johnson: RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer

New designation is based on data showing rapid and durable responses in a heavily pretreated patient population and expands the promise of RYBREVANT FASPRO beyond lung ...